Hiroaki Ozasa

7PUBLICATIONS
59CO-AUTHORS
Molecular targetsMedical infection agents (incl. prions)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 07, 2026
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.

|Dec 10, 2025
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Takahiro Tsuji, Haruka Hirose, Daisuke Sugiyama

|Apr 09, 2025
Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.

Kazutaka Hosoya, Hiroaki Ozasa, Hironori Yoshida

|Mar 06, 2024
Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.

Kazutoshi Isobe, Yasuhiko Nakamura, Susumu Sakamoto

|Dec 05, 2023
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.

Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji

|Dec 14, 2022
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.

Kentaro Tanaka, Kenji Chamoto, Sho Saeki

Pageof 2

Frequent Collaborators

5 joint publications

Takahiro Tsuji

4 joint publications

Kazutaka Hosoya

3 joint publications

Kentaro Hashimoto

3 joint publications

Akihiko Yoshizawa